Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Acton Pharmaceuticals, Inc. to be Acquired by Meda for up to $200 Million

Published: Friday, September 06, 2013
Last Updated: Friday, September 06, 2013
Bookmark and Share
Acton Pharmaceuticals, Inc. announced that it has entered into a definitive agreement under which the Company will be acquired by Meda in an all cash transaction.

The proposed transaction is subject to customary regulatory approvals and standard closing provisions.

Under the terms of the agreement, Meda will acquire 100% of Acton’s shares for $135 million plus $10 million in a contingent, near-term development milestone.  Acton will also receive certain sales-based milestones, which may bring the total potential acquisition value up to $200 million.

Acton is focused on the development of respiratory medicine and recently received U.S. Food and Drug Administration approval for AEROSPAN™ (flunisolide), for the treatment of asthma. AEROSPAN is a HFA-propelled inhaled corticosteroid (ICS) and is the only approved HFA inhaler in its class to incorporate a built-in spacer device, which assists in the delivery of the medicine to the lungs.  The value of the U.S. single-entity ICS market is approaching $2 billion with more than 12 million prescriptions written each year.
 
AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older.

Acton was founded in March 2008 by John Simon, Chief Executive Officer and Daniel Kreisler, President & Chief Operating Officer of Acton.

"Through this transaction with Meda, AEROSPAN will now be commercialized by a company with one of the leading respiratory focused sales forces in the U.S.,” commented Daniel Kreisler.  “We strongly believe this will accelerate the prescribing of this unique inhaled steroid product so we can achieve our goal of making AEROSPAN one of the leading therapies in the $2 billion U.S. inhaled steroid market.”

John Simon continued, “We are excited to enter into this agreement with Meda, a leading global pharmaceutical company.  Meda’s experience marketing respiratory products combined with their significant track record of success makes them extremely well-suited to launch AEROSPAN to respiratory and pediatric physicians in the U.S.”

Scott Carter, a partner at Sequoia Capital and a member of Acton’s Board of Directors said, “We are very fortunate to partner with Acton Pharmaceuticals.  Sequoia Capital recognizes and applauds the excellence of this highly experienced management team who has driven the company to tremendous success.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!